BiotechTube

ibandronate [Bonviva/Boniva] + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Menopausal Osteopenia

Conditions

Post-Menopausal Osteopenia

Trial Timeline

— → Sep 1, 2010

NCT ID
NCT00545207

About ibandronate [Bonviva/Boniva] + Placebo

ibandronate [Bonviva/Boniva] + Placebo is a phase 3 stage product being developed by Roche for Post-Menopausal Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00545207. Target conditions include Post-Menopausal Osteopenia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00545207Phase 3Completed

Competing Products

19 competing products in Post-Menopausal Osteopenia

See all competitors
ProductCompanyStageHype Score
raloxifene + PlaceboEli LillyApproved
85
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
Teriparatide + Zoledronic AcidEli LillyApproved
85
teriparatideEli LillyPhase 3
77
Raloxifene + Raloxifene + PlaceboEli LillyApproved
85
TeriparatideEli LillyApproved
85
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
MK0429MerckPhase 2
52
PTH134 + Placebo + ForsteoNovartisPhase 1
33
Placebo + Zoledronic acidNovartisPhase 3
77
zoledronic acid + Any oral bisphosphonates marketed in CanadaNovartisPre-clinical
23
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
85
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
85
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
85
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
85
IbandronateRochePhase 3
77
romosozumab HCP administration with PFSAmgenPhase 3
76
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo AlendronateAmgenPhase 2
51
BAY3427080 + Placebo (for BAY3427080)BayerPhase 1/2
38

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85